Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer

Anticancer Research

Volumn 29, Issue 10, 2009, Pages 4175-4183

  Al Saad, Samer ^a,b   Donnem, Tom ^a,b   Al Shibli, Khalid ^a,c   Persson, Magnus ^b   Bremnes, Roy M ^a,b   Busund, Lill Tove ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c NORDLAND HOSPITAL   (Norway)

Author keywords

Akt isoforms; NSCLC; Prognosis; Tissue microarray

Indexed keywords

ISOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; THREONINE;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; EPITHELIUM TUMOR; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE; STROMA CELL; SURVIVAL TIME; TISSUE MICROARRAY; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; EPITHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; STROMAL CELLS;

EID: 71949101970     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Al-Saad S, Al Shibli K, Donnem T, Persson M, Bremnes RM, and Busund LT: The prognostic impact of NF-κB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small cell lung cancer. Br J Cancer 2008.
2. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P and Hemmings BA: Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15: 6541-6551, 1996. (Pubitemid 26413787)
3. Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB and Cohen P: Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha. Curr Biol 7: 261-269, 1997.
4. Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, Wang H, Unger M and Testa JR: Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25: 2053-2059, 2004. (Pubitemid 39534841)
5. Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, Bemis L, Gemmill RM, Drabkin HA and Franklin WA: Highthroughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small cell lung cancer. J Clin Oncol 20: 2417-2428, 2002. (Pubitemid 34525727)
6. Brognard J, Clark AS, Ni Y and Dennis PA: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61: 3986-3997, 2001. (Pubitemid 32720961)
7. Cantley LC and Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96: 4240-4245, 1999.
8. Cicenas J, Urban P, Vuaroqueaux V, Labuhn M, Kung W, Wight E, Mayhew M, Eppenberger U and Eppenberger-Castori S: Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. Breast Cancer Res 7: R394-R401, 2005.
9. David O, Jett J, LeBeau H, Dy G, Hughes J, Friedman M and Brady AR: Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res 10: 6865-6871, 2004. (Pubitemid 39383035)
10. Donnem T, Al Saad S, Al Shibli K, Delghandi MP, Persson M, Nilsen MN, Busund LT and Bremnes RM: Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non-small cell lung cancer. Clin Cancer Res 13: 6649-6657, 2007. (Pubitemid 350206800)
11. Goberdhan DC and Wilson C: PTEN: tumour suppressor, multifunctional growth regulator and more. Hum Mol Genet 12 Spec No 2: R239-R248, 2003.
12. Hideshima T, Catley L, Raje N, Chauhan D, Podar K, Mitsiades C, Tai YT, Vallet S, Kiziltepe T, Ocio E, Ikeda H, Okawa Y, Hideshima H, Munshi NC, Yasui H, Richardson PG and Anderson KC: Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol 138: 783-791, 2007. (Pubitemid 47313207)
13. Hutchinson J, Jin J, Cardiff RD, Woodgett JR and Muller WJ: Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 21: 2203-2212, 2001. (Pubitemid 32479640)
14. Itoh N, Semba S, Ito M, Takeda H, Kawata S and Yamakawa M: Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 94: 3127-3134, 2002. (Pubitemid 34670495)
15. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
16. Kim RH, Peters M, Jang Y, Shi W, Pintilie M, Fletcher GC, DeLuca C, Liepa J, Zhou L, Snow B, Binari RC, Manoukian AS, Bray MR, Liu FF, Tsao MS and Mak TW: DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 7: 263-273, 2005. (Pubitemid 40568685)
17. Lee SH, Kim HS, Park WS, Kim SY, Lee KY, Kim SH, Lee JY and Yoo NJ: Non-small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study. APMIS 110: 587-592, 2002.
18. Lin X, Bohle AS, Dohrmann P, Leuschner I, Schulz A, Kremer B and Fandrich F: Overexpression of phosphatidylinositol 3-kinase in human lung cancer. Langenbecks Arch Surg 386: 293-301, 2001. (Pubitemid 32702759)
19. Meier R, Alessi DR, Cron P, Andjelkovic M and Hemmings BA: Mitogenic activation, phosphorylation, and nuclear translocation of protein kinase B beta. J Biol Chem 272: 30491-30497, 1997. (Pubitemid 27512261)
20. Moore SM, Rintoul RC, Walker TR, Chilvers ER, Haslett C, and Sethi T: The presence of a constitutively active phosphoinositide 3-kinase in small cell lung cancer cells mediates anchorage-independent proliferation via a protein kinase B and p70s6k-dependent pathway. Cancer Res 58: 5239-5247, 1998. (Pubitemid 28521188)
21. Mountain CF: The international system for staging lung cancer. Semin Surg Oncol 18: 106-115, 2000. (Pubitemid 30090451)
22. Nicholson KM and Anderson NG: The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 14: 381-395, 2002.
23. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
24. Persad S, Attwell S, Gray V, Delcommenne M, Troussard A, Sanghera J and Dedhar S: Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA 97: 3207-3212, 2000. (Pubitemid 30183280)
25. Shah A, Swain WA, Richardson D, Edwards J, Stewart DJ, Richardson CM, Swinson DE, Patel D, Jones JL and O'Byrne KJ: Phospho-akt expression is associated with a favorable outcome in non-small cell lung cancer. Clin Cancer Res 11: 2930-2936, 2005. (Pubitemid 40525195)
26. Tang JM, He QY, Guo RX and Chang XJ: Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51: 181-191, 2006.
27. Toloza EM and D'Amico TA: Targeted therapy for non-small cell lung cancer. Semin Thorac Cardiovasc Surg 17: 199-204, 2005. (Pubitemid 41614077)
28. Tsao AS, McDonnell T, Lam S, Putnam JB, Bekele N, Hong WK, and Kurie JM: Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev 12: 660-664, 2003. (Pubitemid 36899849)
29. Tsurutani J, Fukuoka J, Tsurutani H, Shih JH, Hewitt SM, Travis WD, Jen J and Dennis PA: Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small cell lung cancer tumors. J Clin Oncol 24: 306-314, 2006. (Pubitemid 46622059)
30. Tsurutani J, Steinberg SM, Ballas M, Robertson M, LoPiccolo J, Soda H, Kohno S, Egilsson V and Dennis PA: Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. Lung Cancer 55: 115-121, 2007. (Pubitemid 46038882)
31. Vanhaesebroeck B and Alessi DR: The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 346 Pt 5: 561-576, 2000. (Pubitemid 30171014)
32. Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, Wang J, Erdjument-Bromage H, Tempst P, Cordon-Cardo C, Pandolfi PP and Jiang X: NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128: 129-139, 2007. (Pubitemid 46048884)
33. Travis William D, Brambilla E, Müller-Hermelink HK and Harris C: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, IARC Press, 2004.
34. Zafrani B, Aubriot MH, Mouret E, De Cremoux P, De Rycke Y, Nicolas A, Boudou E, Vincent-Salomon A, Magdelenat H and Sastre-Garau X: High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathology 37: 536-545, 2000. (Pubitemid 32099165)